We found that treatment with Bev (10 mg/kg) + anti-CD47 (5 mg/kg), Bev (10 mg/kg) + anti-CD47 (10 mg/kg), and Bev (10 mg/kg) + anti-CD47 (20 mg/kg) decreased the microvessel density of xenograft tumours to 2.21 ± 1.17‰, 2.19 ± 0.81‰, and 1.59 ± 0.08‰, respectiveiy, compared to that of treatment with Bev group (2.46 ± 0.09‰). This evidence concerns the gene CD47 and neoplasm.